* Chiron Corp., of Emeryville, Calif., and its partner, DepoTechCorp., of San Diego, said their anti-cancer drug, DepoCyt, extendedsurvival of patients with neoplastic meningitis associated with cancermetastasis. The DepoCyt treated patients were evaluated in a PhaseIII trial against a control group receiving methotrexate. In June 1996the companies said findings from the Phase III study showed patientsreceiving DepoCyt experienced a higher complete response ratecompared with methotrexate. DepoCyt is a sustained release form ofcytarabine, a chemotherapy agent, encapsulated in DepoFoam,DepoTech's lipid-based drug delivery system.

* Genzyme Transgenics Corp., of Framingham, Mass., said a Phase Itrial of antithrombin III, a plasma protein produced in the milk oftransgenic goats, was safe. The proteins are made by creating goatswhose cells have been altered with human DNA so they secreteantithrombin III, which is used to prevent blood clotting. Thecompany, which is nearly 45 percent owned by Genzyme Corp., ofCambridge, Mass., said it has filed for approval with the FDA tobegin a Phase II trial of the transgenic protein to reduce bleeding inpatients undergoing heart bypass surgery.

(c) 1997 American Health Consultants. All rights reserved.